Eurofins Scientific share hits highest level since 2022 and targets €80
Eurofins Scientific crosses on Friday an unprecedented threshold since 2022, bringing its rebound to nearly 10% over the week in a CAC 40 that declines by 0.76% in trading. The stock clearly stands out from a Parisian index under pressure, benefiting from a bullish momentum that has accelerated since the beginning of the month.
A four-year record broken during trading, well above the three moving averages
The Eurofins Scientific share touched €77.84 in trading, breaking its previous four-year record dating back to 2022 (€77.80), a year marked by the war in Ukraine and the rate hike cycle. The current price stands at €77.84, up 1.25% compared to the previous close (€76.88), which also represents the upward breakthrough of the former resistance at €76.88. The stock is now clearly evolving above its three moving averages: it exceeds the MA20 at €72.65 by a margin of 7.14%, the MA50 at €70.59 by more than 10% and the MA200 at €65.99 by nearly 18%.
This configuration reflects consistent bullish momentum across several timeframes, especially since the one-month performance exceeds 11% and the three-month performance reaches 24.46%. The RSI at 73 signals an overbought configuration, which is consistent with the amplitude of the recent movement. The next prospective reference point is located around the psychological level of €80, a level that no previous technical resistance marks.
Interim results pointing towards 2027 with increased cash generation
To provide substance to this price movement, one must go back to the first half 2026 results, published on July 23, 2026. Management had then adopted a confident tone, noting that profitability was already approaching the target set for 2027, with more than a year in advance, and that the reduction in investments was contributing to significantly higher cash generation. Among the points of concern mentioned during this publication, organic revenue growth had not yet returned to a normal level in the early part of the semester, and BioPharma activities (particularly ancillary activities in North America) remained lagging.
On the outlook front, management anticipated a recovery in ancillary BioPharma activities in the second half of 2026, and the acquisition of Element Materials Technology in North America (more than $150 million in annual revenues) was expected for the fourth quarter 2026. In a market context where the VIX falls to 15.33 (compared to 17.71 the previous day, a decline of 13.44%), risk appetite is improving in trading, which favors stocks in established bullish trend. The €80 level constitutes the next reference point to monitor to measure the persistence of the current momentum.
